Tubize Fin (Belgium) Today
| TUB Stock | EUR 138.40 2.20 1.62% |
Performance9 of 100
| Odds Of DistressLess than 39
|
Tubize Fin is selling at 138.40 as of the 27th of November 2024; that is 1.62% increase since the beginning of the trading day. The stock's lowest day price was 136.6. Tubize Fin has about a 39 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Tubize Fin are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 8th of December 2022 and ending today, the 27th of November 2024. Click here to learn more.
Financire de Tubize S.A., through its interest in UCB, operates as a biopharmaceutical company worldwide. The companys products in pipeline include UCB0942 for drug resistant epilepsy UCB3491 for infantile epilepsy UCB0599 for Parkinsons disease UCB7858UCB0159 for auto-inflammatory diseases UCB6673 to treat immunological diseases UCB4144VR942 to treat asthma seletalisib for treating Sjrgens syndrome dapirolizumab pegol for systemic lupus erythematosus bimekizumab to treat psoriasis, psoriatic arthritis, and ankylosing spondylitis rozanolixizumab to treat immune thrombocytopenia and myasthenia gravis and romosozumab for post-menopausal osteoporosis and osteoporosis in men. The company has 44.48 M outstanding shares. More on Tubize Fin
Moving against Tubize Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Tubize Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Tubize Fin's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Tubize Fin or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) |
Tubize Fin (TUB) is traded on Euronext Brussels in Belgium and employs 12 people. The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.34 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Tubize Fin's market, we take the total number of its shares issued and multiply it by Tubize Fin's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Tubize Fin operates under Pharmaceuticals sector and is part of Health Care industry. The entity has 44.48 M outstanding shares.
Tubize Fin has accumulated about 1.02 M in cash with (1.16 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02.
Check Tubize Fin Probability Of Bankruptcy
Ownership AllocationTubize Fin shows a total of 44.48 Million outstanding shares. Tubize Fin maintains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Tubize Ownership Details
Tubize Fin Risk Profiles
Although Tubize Fin's alpha and beta are two of the key measurements used to evaluate Tubize Fin's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 1.33 | |||
| Semi Deviation | 1.93 | |||
| Standard Deviation | 1.85 | |||
| Variance | 3.41 |
Tubize Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Tubize Fin without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Bonds Directory Now
Bonds DirectoryFind actively traded corporate debentures issued by US companies |
| All Next | Launch Module |
Additional Tools for Tubize Stock Analysis
When running Tubize Fin's price analysis, check to measure Tubize Fin's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tubize Fin is operating at the current time. Most of Tubize Fin's value examination focuses on studying past and present price action to predict the probability of Tubize Fin's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tubize Fin's price. Additionally, you may evaluate how the addition of Tubize Fin to your portfolios can decrease your overall portfolio volatility.